Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2008-01-29
Richter, Johann (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S561000, C548S562000
Reexamination Certificate
active
07323491
ABSTRACT:
The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing themThis invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5861173 (1999-01-01), Nishioka et al.
patent: 5885997 (1999-03-01), Lohray et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5889032 (1999-03-01), Lohray et al.
patent: 5985884 (1999-11-01), Lohray et al.
patent: 6048883 (2000-04-01), Haigh et al.
patent: 6054453 (2000-04-01), Lohray et al.
patent: 6130214 (2000-10-01), Lohray et al.
patent: 6159966 (2000-12-01), Lohray et al.
patent: 6166049 (2000-12-01), Smith
patent: 6265401 (2001-07-01), Lohray et al.
patent: 6294586 (2001-09-01), Yelle et al.
patent: 6313113 (2001-11-01), Lohray et al.
patent: 6362360 (2002-03-01), Andersson et al.
patent: 6369067 (2002-04-01), Gurram et al.
patent: 6440961 (2002-08-01), Lohray et al.
patent: 6444816 (2002-09-01), Das et al.
patent: 6521622 (2003-02-01), Ricks et al.
patent: 6525083 (2003-02-01), Acton, III et al.
patent: 6569901 (2003-05-01), Mogensen et al.
patent: 6573628 (2003-06-01), Sloupensky et al.
patent: 6589969 (2003-07-01), Tajima et al.
patent: 6602901 (2003-08-01), Jeppesen et al.
patent: 6987123 (2006-01-01), Lohray et al.
patent: 0753 298 (1997-01-01), None
patent: 90 3343 (1999-03-01), None
patent: WO 91/19702 (1991-12-01), None
patent: WO 94/01420 (1994-01-01), None
patent: WO 94/13650 (1994-06-01), None
patent: WO 94/29302 (1994-12-01), None
patent: WO 95/03038 (1995-02-01), None
patent: WO 95/17394 (1995-06-01), None
patent: WO 96/04260 (1996-02-01), None
patent: WO 96/04261 (1996-02-01), None
patent: WO 96/33998 (1996-10-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 97/31970 (1997-09-01), None
patent: WO 97/36579 (1997-10-01), None
patent: WO 98/02159 (1998-01-01), None
patent: WO 98/28534 (1998-07-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/19313 (1999-04-01), None
patent: WO 99/20614 (1999-04-01), None
patent: WO 99/38850 (1999-08-01), None
patent: WO 00/23417 (2000-04-01), None
patent: WO 00/23445 (2000-04-01), None
patent: WO 00/23451 (2000-04-01), None
patent: WO 01/53257 (2001-07-01), None
J Hypertens Suppl. Sep. 2001;19 Suppl 3:S17-21, “The choice of first-line therapy: rationale for low-dose combinations of an angiotensin converting enzyme inhibitor and a diuretic.”
Diabetes Obes Metab. May 1999; 1 Suppl 1:S41-8, “Promising new approaches.”
J Hypertens Suppl. Jan. 1998;16(1):S35-7, “Obesity in hypertension: effects on prognosis and treatment.”
Nurse Pract. Jun. 1996;21(6):74-5, 79-80, 83-6, “Syndrome X. Recognition and management of this metabolic disorder in primary care.”
Postgrad Med. May 2003;Spec No. 27-34, “Insulin resistance syndrome. Description, pathogenesis , and management.”
Am J Cardiol. Apr. 3, 2003;91(7A):18E-39E, “Effects of Nonstatin Lipid Drug Therapy on High-Density Lipoprotein Metabolism.”
Am J Cardiol. Apr. 3, 2003;91(7A):18E-39E, “Management of Patients with diabetic hyperlipidemia.”
Am J Cardiol. Apr. 3, 2003;91(7A):18E-39E, “Treatment of patients with Metabolic Syndrome.”
Cardiovasc Drugs Ther. Sep. 2002;16(5):457-70, “Beta-blockers and diabetes: the bad guys come good.”
Curr Drug Targets. Jun. 2002; 3(3): 203-21, “Multiple drug targets in the management of type 2 diabetes.”
Annals of Internal Medicine, Aug. 1999; 131(4): 281-303, “Pharmacologic Therapy for Type 2 Diabetes Mellitus.”
Diabetes Mellitus—A Fundamental Text book, p. 769-811, “Insulin Secretgogues Sulfonylureas and Meglitinides.”
Detection Evaluation and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III)-“Drug Therapy.”
Int J Clin Pract Suppl. Oct. 2000; (113): 54-62, “Current treatment of insulin resistance in type 2 diabetes mellitus.”
Diabet Med. 1998; 15 Suppl 4:S13-9, “Improving glycaemic control with current therapies.”
Am J Manag Care. Oct. 2002; 8(16 Suppl): S460-71, “Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.”
A. N. Collins, G. N. Sheldrake and J. Crosby, in “Chirality in Industry II”, John Wiley & Sons, Inc., 1997, 81-98 and references therein.
Cancer Research, 58, 3344-3352 (1998).
Carcinogenesis, vol. 19 No. 11, 1949-1953 (1998).
Cell, 87, 377-389 (1996).
Cell, 55, 932-943 (1999).
Cell, 79, 1147-1156 (1994).
Cell, 83, 803-812 (1995).
Cell, 99, 239-242 (1999).
Cell Biology, 95, 14751-14756 (1998).
Current Biol., 5, 618-621 (1995).
E. L. Eliel and S. H. Wilen, in “Stereochemistry of Organic Compound”, John Wiley & Sons, Inc., 1994, 297-464 and references therein.
Endocrine Reviews, 20(5), 649-688 (1999).
Endocrinology 135, 798-800 (1994).
Exp. Clin. Endocrinol. Diabetes: 109(4), S548-559 (2001).
T. W. Greene and P. G. M. Wuts “Protective Groups in Organic Synthesis”, John Wiley & Sons, Inc., 1999, 3rdEd., 201-245 along with references therein.
J. Clin. Invest., 85, 962-967, 1990.
J. Medicinal Chemistry, 43(4), 527-550 (2000).
Jaques et al. “Enantiomers, Racemates and Resolution”, Wiley Interscience, 1981.
Knorr, L., Ber., 1885, 18, 299-311.
Macikinnon et al., J. Biol. Chem. 261, 2548-2552 (1986).
Med. Res. Rev., 20(5), 350-366 (2000).
Miller et al., Br. Med. J. 282, 1741-1744 (1981).
Molecular Cell, 465-470 (1998).
Nature Reviews: Drug Discovery: 1(4), 276-86 (2002).
Nature, 405, 421-424 (2000).
Paal C. Ber., 1885, 18, 367-371.
Petit D., Bonnefis M. T., Rey C. and Infante R., Effects of ciprofibrate on liver lipids and lipoprotein synthesis in normal and hyperlipidemic rats, Atherosclerosis, 74, 215-225 (1988).
Picardo et al., Arteriosclerosis, 6, 434-441 (1986).
Principles of Asymmetric Synthesis J E Baldwin Ed. Tetrahedron series, vol. 14, Page No. 311-316.
Proc. Natl. Acad. Sci. 93, 5793-5796 (1996).
Proc. Natl. Acad. Sci., 94, 237-241 (1997).
Remington: the Science and Practice of Pharmacy, 19thEd., 1995.
Ross and Glomset, New Engl. J. Med., 295, 369-377 (1976).
Science, 269, 543-46 (1995).
R. A. Sheldon, in “Chirotechnology”, Marcel Dekker, Inc. NY, Basel, 1993, 173-204 and references therein.
Stampfer et al., N. Eng. J. Med., 325, 373-381 (1991).
Trends Endocrine. Metabolism, 4, 291-296 (1993).
Trends in Pharmacological Sci., 469-473 (2000).
Trinder, P. Ann. Clin. Biochem. 1969. 6: 24-27.
Wieland, O. Methods of Enzymatic Analysis. Bergermeyer, H., O., Ed., 1963. 211-214.
DDT, vol. 6, No. 13, 2001, p. 654-55, “Unravelling metabolic syndrome X.”
Diabetes Mellitus—A Fundamental Text book, pp. 326-329,611-613, “Definition and Classification of Diabetes Mellitus and the New Criteria for Diagnosis.”
Am Heart J. Dec. 1988; 116(6 Pt 2): 1713-24 “The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.”
3rd Report of the National Cholesterol Education Program (NCEP), Expert Panel on ‘Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)’-NIH, USA.
Diabetes Mellitus—A Fundamental Text book, pp. 326
Barot Vijay Kumar Gajubhai
Lohray Braj Bhushan
Lohray Vidya Bhushan
Cadila Healthcare Limited
Kelley Drye & Warren LLP
Richter Johann
Sackey Ebenezer
LandOfFree
Heterocyclic compounds, their preparation, pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, their preparation, pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds, their preparation, pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764129